Please assess the completion status of the following clinical trial:

Trial Title: Study in Hepatitis C Virus (HCV) Infected Patients Undergoing Liver Transplantation to Evaluate a Human Monoclonal Antibody Against Hepatitis C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient ≥ 18 years of age with documented chronic hepatitis C virus infection of genotype 1a undergoing liver transplantation from either a deceased donor or living donor.~* Patient or legal guardian/health care proxy must have read, understood and provided written informed consent and HIPAA authorization after the nature of the study has been fully explained.~Exclusion Criteria:~* Positive serology for Hepatitis B surface Antigen~* Positive serology for HIV~* Pregnancy or breastfeeding~* Previous history of any organ transplant~* Planned receipt of combined organ transplant (e.g. liver and kidney)~* Receipt or planned receipt of immune globulin (IVIG) within 90 days of enrollment~* History of extrahepatic malignancy and/or receiving chemotherapy within 90 days prior to enrollment with the exception of chemoembolization for hepatocellular carcinoma~* Hepatocellular carcinoma with tumor burden outside of the Milan criteria~* History of chronic renal insufficiency or creatinine \> 2.5 for ≥ six months~* Personal or family history of deep venous thrombosis or pulmonary embolism~* Receipt of liver allograft from HCV positive donor or Hepatitis B core antibody positive donor~* Receipt of liver allograft donated after cardiac death of donor~* Receipt of any antiviral agents, licensed or investigational for hepatitis C virus within 90 days prior to enrollment~* Receipt of any other investigational study product within 30 days prior to enrollment~* Any other condition that in the opinion of the investigator would jeopardize the safety or rights of the patient participating in the study or make it unlikely that the patient could complete the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MBL-HCV1 (Type: EXPERIMENTAL): None
- 0.9% sodium chloride (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).